These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22023903)

  • 1. Teriparitide update.
    Silverman SL; Nasser K
    Rheum Dis Clin North Am; 2011 Aug; 37(3):471-7, vii. PubMed ID: 22023903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
    Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
    J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Back pain treatment in post-menopausal osteoporosis with vertebral fractures.
    Ulivieri FM
    Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):21-3. PubMed ID: 18180603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Pharmacologic Therapy in Postmenopausal Osteoporosis.
    Shen Y; Gray DL; Martinez DS
    Endocrinol Metab Clin North Am; 2017 Mar; 46(1):193-206. PubMed ID: 28131133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Teriparatide: an anabolic drug for the treatment of patients with osteoporosis].
    Lems WF; Hamdy NA; Netelenbos JC
    Ned Tijdschr Geneeskd; 2006 Jan; 150(3):132-7. PubMed ID: 16463613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recognition of women at risk for fracture and intervention with fast-acting therapies.
    Derman R
    Int J Fertil Womens Med; 2006; 51(4):183-90. PubMed ID: 17184104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anabolic therapy for osteoporosis.
    Bilezikian JP
    Int J Fertil Womens Med; 2005; 50(2):53-60. PubMed ID: 16334411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of teriparatide in sequential and combination therapy of osteoporosis.
    Meier C; Lamy O; Krieg MA; Mellinghoff HU; Felder M; Ferrari S; Rizzoli R
    Swiss Med Wkly; 2014; 144():w13952. PubMed ID: 24896070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postmenopausal women with osteoporosis: experience when treated with teriparatide in clinical practice.
    Ish-Shalom S; Dumitrache C; El-Husseini TF; Hussein A; Barker C; Pavo I
    Curr Med Res Opin; 2011 Feb; 27(2):343-53. PubMed ID: 21166609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
    Adachi JD; Hanley DA; Lorraine JK; Yu M
    Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reclast approved for osteoporosis treatment in postmenopausal women.
    Laustsen G
    Nurse Pract; 2007 Dec; 32(12):12-4. PubMed ID: 18043404
    [No Abstract]   [Full Text] [Related]  

  • 14. [Teriparatide--new value in osteoporosis treatment: treatment guidelines].
    Korsić M; Kastelan D
    Reumatizam; 2006; 53(2):77-81. PubMed ID: 17580560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
    Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC
    J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
    Marcus R; Wang O; Satterwhite J; Mitlak B
    J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Daily subcutaneous injection of teriparatide : the progress and current issues].
    Yano S; Sugimoto T
    Clin Calcium; 2014 Jan; 24(1):35-43. PubMed ID: 24369278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of osteoporosis: bisphosphonates, SERM's, teriparatide and strontium].
    Uebelhart D; Frey D; Frey-Rindova P; Goerres G; Michel BA
    Z Rheumatol; 2003 Dec; 62(6):512-7. PubMed ID: 14685711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of fracture non-union in a young adult with combination anabolic and anti-resorptive bone therapy.
    Corrigan RA; Miller A; McNally MA; Javaid MK
    Rheumatology (Oxford); 2013 Jun; 52(6):1147-9. PubMed ID: 23241394
    [No Abstract]   [Full Text] [Related]  

  • 20. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
    Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
    Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.